Ind-Swift Laboratories Limited has completed a significant preferential allotment of equity shares following the conversion of fully convertible warrants by promoter group entity Essix Biosciences Limited. The transaction has triggered comprehensive regulatory disclosure requirements under SEBI regulations.

Warrant Conversion and Allotment Details

The Preferential Issue Committee of the Board of Directors approved the allotment during their meeting held on February 24, 2026. The allotment involved the conversion of 51,00,000 fully convertible warrants into equity shares by Essix Biosciences Limited, originally allotted on August 30, 2024.

Regulatory Compliance and Disclosure

Essix Biosciences Limited, represented by Director Himanshu Jain, filed comprehensive disclosures under multiple SEBI regulations on February 26, 2026. The company submitted notifications under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Impact on Share Capital Structure

Following the completion of this preferential allotment, Ind-Swift Laboratories' capital structure has been significantly enhanced. The paid-up equity share capital increased from ₹81,61,15,580 to ₹86,71,15,580, representing an addition of ₹5.10 crores.

Promoter Group Structure

The disclosure reveals that Essix Biosciences Limited acts in concert with 19 persons acting in concert (PACs), including key individuals such as Nidhi Munjal, Meenakshi Mehta, Ravi Mehta, Neeta Munjal, Himanshu Jain, Sunita Jain, Gopal Munjal, Saurabh Munjal, and others from the promoter families.

Ind-Swift Laboratories informed both NSE and BSE about the substantial acquisition through official communications dated February 27, 2026, ensuring full regulatory compliance under applicable takeover and insider trading regulations. The preferential allotment was conducted in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Ind-Swift Laboratories Limited has filed its quarterly monitoring agency report for the quarter ended December 31, 2025, concerning the utilization of funds raised through its preferential issue of fully convertible warrants worth Rs. 314.60 crore. The report, prepared by CARE Ratings Limited as the appointed monitoring agency, provides insights into the deployment and utilization of the raised capital.

Fund Utilization Status

The monitoring report reveals that no proceeds were utilized during Q3FY26, with the company maintaining Rs. 0.46 crore as unutilized funds at the quarter's end. The preferential issue, which involved fully convertible warrants allotted on August 30, 2024, has an 18-month exercise period for warrant holders.

Key Monitoring Observations

The monitoring agency confirmed several important aspects of fund management:

• No Deviations: All utilization remains aligned with the disclosures in the offer document
• Regulatory Compliance: No material deviations requiring shareholder approval were observed
• Statutory Approvals: Relevant approvals mentioned in the placement document are in place, with additional approvals to be obtained as required for specific projects

Temporary Fund Movement

The report highlighted a notable transaction during Q3FY26 where Rs. 0.45 crore was temporarily transferred from the preferential issue account to the company's current account. This transfer was made in anticipation of a land purchase transaction but was reversed after 69 days when the transaction could not be finalized within expected timelines. The company clarified that there was no diversion or misuse of preferential issue proceeds at any point.

Market Volatility Concerns

The monitoring agency noted that the company's share price experienced high volatility during the three months ended December 31, 2025, even falling below the warrant exercise price in December 2025. This development could potentially affect warrant holders' decisions regarding conversion, which may impact the viability of the stated objects if warrants are allowed to lapse.

Implementation Timeline

The company has successfully completed the utilization of funds allocated for working capital requirements and general corporate purposes ahead of schedule, both being fully deployed in Q2FY26. The remaining categories continue to progress according to their respective timelines, with no delays reported in the implementation of stated objects.